Onkologie. 2025:19(5):288-293 | DOI: 10.36290/xon.2025.052

New trends in local and systemic treatment of uveal melanoma

Eva Skácelíková

Klinika onkologická, Fakultní nemocnice Ostrava a Lékařská fakulta Ostravské univerzity v Ostravě

Uveal melanoma is the most common malignant tumor of the eye in adult patients. Although its incidence is relatively low, the disease is associated with a high risk of local recurrence and distant metastases, particularly to the liver. Traditional treatment strategies include enucleation, brachytherapy, or proton radiotherapy; in recent years, stereotactic radiotherapy (SRT) has become increasingly popular in clinical practice, offering precise application of high doses of radiation with a high degree of local control and preservation of the eyeball. Systemic treatment of metastatic disease is a completely separate issue. Until recently, there was no effective therapy capable of influencing overall survival. A significant shift came with tebentafusp (Kimmtrak), the first TCR-bispecific immunotherapy approved on the basis of proven prolongation of overall survival in HLA-A*02:01-positive patients with metastatic uveal melanoma. The aim of this paper is to summarize the current status of stereotactic radiotherapy and the new systemic treatment with tebentafusp in the therapy of uveal melanoma.

Keywords: uveal melanoma, brachytherapy, proton radiotherapy, stereotactic radiotherapy, tebentafusp.

Accepted: November 25, 2025; Published: December 15, 2025  Show citation